WASHINGTON — In a historic milestone for oncology, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to daraxonrasib (brand name Rasonque), clearing the world's first targeted RAS inhibitor for patients battling metastatic pancreatic ductal adenocarcinoma.
 |
| FDA Approves Daraxonrasib Pancreatic Cancer Treatment Breakthrough 2026 |
Overcoming Medicine's Most Intractable Cancer Target
Developed by Revolution Medicines, the daily oral therapy directly attacks mutated RAS oncogenes responsible for driving aggressive tumor cell replication in over 90% of pancreatic cancer cases:
- Doubled Survival Benchmark: In late-stage phase 3 clinical trials, patients taking daraxonrasib achieved a median overall survival of 13.2 months compared to 6.7 months for standard cytotoxic chemotherapy regimens.
- Early Regulatory Clearance: Recognizing unprecedented trial data that cut the risk of mortality by 60%, federal health regulators cleared the drug months ahead of statutory deadlines.
- Patient-Centric Oral Delivery: Unlike multi-hour intravenous chemotherapy infusions, daraxonrasib provides a manageable daily pill formulation that significantly reduces severe systemic toxicity.
Also Read: Nvidia Acquires AI Giant Hugging Face in $12.9B Mega-Deal
Clinical Timeline & Approval Milestone
- Early 2026 (Global Trials): Multicenter Phase 3 trials demonstrated marked progression-free survival and tumor stabilization across international patient cohorts.
- July 2026 (Expedited Priority Review): The FDA accepted the application under expedited priority voucher protocols due to extreme unmet clinical need.
- August 26–27, 2026 (Global Market Authorization): The FDA officially authorized Rasonque, establishing a new global standard of care for refractory solid tumors.
Why This Matters Globally
Pancreatic cancer remains among the deadliest malignant diagnoses globally, burdened with a five-year relative survival rate under 15%. Validating the multi-selective RAS inhibitor mechanism unlocks new clinical pathways to target lung and colorectal solid tumors worldwide.
Related Coverage on ViralScope Official:
0 Comments